MiR-181b Regulates Cisplatin Chemosensitivity and Metastasis by Targeting TGFβR1/Smad Signaling Pathway in NSCLC

Overview

Journal Sci Rep

Specialty Science

Date 2015 Dec 2

PMID 26620926

Citations 41

Authors

Xiaoyuan Wang

Xuesong Chen

Qingwei Meng

Hu Jing

Hailing Lu

Yanmei Yang

Li Cai

Yanbin Zhao

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) have been identified as important post-transcriptional regulators involved in various biological and pathological processes of cells, but their underlying mechanisms in chemosensitivity and metastasis have not been fully elucidated. The objective of this study was to identify miR-181b and its mechanism in the chemosensitivity and metastasis of NSCLC. We found that miR-181b expression levels were lower in A549/DDP cells compared with A549 cells. Functional assays showed that the overexpression of miR-181b inhibited proliferation, enhanced chemosensitivity to DDP, attenuated migration and metastatic ability in NSCLC cell lines in vitro and in vivo. TGFβR1 was subsequently identified as a novel functional target of miR-181b. TGFβR1 knockdown revealed similar effects as that of ectopic miR-181b expression, whereas overexpression of TGFβR1 rescued the function of miR-181b-mediated growth, chemosensitivity and metastasis in NSCLC cells. In addition, miR-181b could inactivate the TGFβR1/Smad signaling pathway. We also observed that decreased miR-181b expression and increased TGFβR1 expression were significantly associated with chemosensitivity to DDP and tumor metastasis in NSCLC patients. Consequently, miR-181b functions as a tumor suppressor and has an important role in proliferation, chemosensitivity to DDP and metastasis of NSCLC by targeting TGFβR1/Smad signaling pathway.

Citing Articles

PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma.

Wang Y, Wang C, Guan X, Ma Y, Zhang S, Li F Adv Sci (Weinh). 2023; 10(36):e2303812.

PMID: 37973560 PMC: 10754120. DOI: 10.1002/advs.202303812.

Identification of non-coding RNA related prognosis biomarkers based on ceRNA network in thyroid cancer.

Fang X, Chen X, Gao J, Tong L Front Genet. 2023; 14:1157438.

PMID: 37153003 PMC: 10158935. DOI: 10.3389/fgene.2023.1157438.

Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer.

Mondal P, Meeran S Front Pharmacol. 2023; 14:1105484.

PMID: 36778005 PMC: 9909610. DOI: 10.3389/fphar.2023.1105484.

Micro-ribonucleic acids (miRNAs) and a proteomic profile in lung adenocarcinoma cases with brain metastasis.

Zhang L, Liang J, Han Z, Wang L, Liang J, Zhang S Ann Transl Med. 2023; 10(24):1389.

PMID: 36660652 PMC: 9843405. DOI: 10.21037/atm-22-5703.

MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going.

Cuttano R, Afanga M, Bianchi F Cancers (Basel). 2022; 14(23).

PMID: 36497213 PMC: 9740066. DOI: 10.3390/cancers14235731.

References

Yang J, Liu H, Wang H, Sun Y . Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer. Pathol Res Pract. 2013; 209(8):490-4. DOI: 10.1016/j.prp.2013.04.018. View

Boeri M, Pastorino U, Sozzi G . Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012; 18(3):268-74. DOI: 10.1097/PPO.0b013e318258b743. View

Papageorgis P . TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015; 2015:587193. PMC: 4389829. DOI: 10.1155/2015/587193. View

Almeida M, Reis R, Calin G . MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011; 717(1-2):1-8. DOI: 10.1016/j.mrfmmm.2011.03.009. View

Besse A, Sana J, Fadrus P, Slaby O . MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol. 2013; 34(4):1969-78. DOI: 10.1007/s13277-013-0772-5. View

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

Chen Y, Gelfond J, McManus L, Shireman P . Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682. Physiol Genomics. 2010; 43(10):621-30. PMC: 3110887. DOI: 10.1152/physiolgenomics.00136.2010. View

Yang L, Wang Y, Liu S, Zhang P, Chen Z, Liu M . miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett. 2013; 588(1):124-30. DOI: 10.1016/j.febslet.2013.11.019. View

10.

Hjelmeland M, Hjelmeland A, Sathornsumetee S, Reese E, Herbstreith M, Laping N . SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004; 3(6):737-45. View

11.

Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J . MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer. FASEB J. 2014; 28(6):2696-704. DOI: 10.1096/fj.13-247288. View

12.

Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P . Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014; 14:448. PMC: 4075993. DOI: 10.1186/1471-2407-14-448. View

13.

Wakefield L, Roberts A . TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002; 12(1):22-9. DOI: 10.1016/s0959-437x(01)00259-3. View

14.

Schmierer B, Hill C . TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007; 8(12):970-82. DOI: 10.1038/nrm2297. View

15.

Zhai H, Ju J . Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. Front Genet. 2011; 2(78). PMC: 3221387. DOI: 10.3389/fgene.2011.00078. View

16.

Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X . Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One. 2011; 6(8):e23271. PMC: 3158077. DOI: 10.1371/journal.pone.0023271. View

17.

Ikushima H, Miyazono K . TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010; 10(6):415-24. DOI: 10.1038/nrc2853. View

18.

Bierie B, Moses H . Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006; 6(7):506-20. DOI: 10.1038/nrc1926. View

19.

Xia Y, Gao Y . MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014; 447(3):446-51. DOI: 10.1016/j.bbrc.2014.04.027. View

20.

Chen L, Yang Q, Kong W, Liu T, Liu M, Li X . MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. IUBMB Life. 2012; 64(7):628-35. DOI: 10.1002/iub.1030. View